
1. Assignment of the Department of Dermatology USZ
2. Mission Statement
3. Team
4. Patient Care
5. Public Relations
6. Research Foundations
7. Research
8. Medical Education / Teaching
9. Partners / Sponsors / Collaboration with Industry and Fund Raising
10. Honors and Prizes
11. Previews
12. Publications
I am pleased, in the name of the entire Team of our Dermatology Department, to share with you our biennial report for the years 2007 and 2008.

It gives me great pleasure to look back over the previous two years and review the significant accomplishments of our department, faculty and staff.

The years 2007 and 2008 were times of significant reorganisation and change in the department, following the retirement in March 2006 of former chairman Prof Günter Burg, and my nomination to chair the department in October 2006 after a very successful interim management period by Prof Reinhard Dummer. Reform and organisational improvement were absolutely necessary, in order to be well prepared for future challenges in the medical field. The staff of our department has made a variety of important improvements in organisational structure and clinical services during the past two years. These include the implementation of a new participative management structure, the implementation of a new «organigram» composed of distinct clinical divisions «Bereiche» under the responsibility of distinct faculty members. A further priority has been the development of a trustful environment with a constructive error culture, the latter being supported by the implementation of an online critical incident reporting system. To improve patient service in face of over 95’000 patient consultations per year, we have installed a centralised patient registration and appointment system. And last but not least we have implemented measures to decrease the administrative load of work that faces our residents, so that they have more time for our patients and personal medical education.

New clinical activities and structures were also launched during 2007 and 2008, notably the pigmented lesion and skin cancer prevention clinic under the direction of PD Dr Ralph Braun and the inpatient week clinic - that provides short diagnostic workups and short therapy possibilities on the E Floor - under the direction of PD Dr Günther Hofbauer.

Our department is devoted to providing sustained leadership in patient care, research and education in the fields of dermatology, venerology and allergology. Our faculty and staff particularly honour their educational commitment to medical and nursing students, to residents in dermatology training, and to postgraduate teaching for established specialists in dermatology and allergology. Under my direction and that of PD Dr Peter Schmid, and in collaboration with over 14 faculty members and external private physicians or colleagues, we currently provide pregraduate dermatology training to over 200 students yearly in the 3rd, 4th, 5th and 6th year of medical education. We also host over 50 medical students per year for 1 – 4 months of practical training in the clinic. This offer and the professionalism of faculty members teaching is particularly appreciated by students in Switzerland and within Europe, approximately 50% of the students originating from Universities outside of Switzerland. 22 residents are currently performing their 5 years of specialised dermatology training in our clinic, an activity that is essential for maintaining high quality patient care in dermatology in Switzerland. In 2007 and 2008 we have significantly developed our postgraduate and continuing medical education program, offering over 12 CME events and grand rounds per year, many of which attract 180 – 200 participants. Furthermore we have added a dermatology update series to our postgraduate teaching, with the aim of providing a further platform for case presentations, short updates, and an overview of important publications in dermatology via our journal club.

The main academic focus of our department is dermato-oncology, immuno-dermatology, and allergology. In experimental as well as clinical research 2007 and 2008 were extremely
successful years. The innovative character of the research produced by our highly productive research team of over 50 scientists and clinician-scientists is illustrated by several high impact publications including an article concerning the mechanism of development of psoriasis in Nature Medicine in 2007, and the strong rise in the departments cumulative impact factor between 2006 and 2008. Accumulated impact factor measures the quantity and quality of research, and its progression from 190 points in 2006 to 355 in 2008, positions us among the leading academic dermatology departments in the world. Our department sets a high priority for clinical research too. This is the best way to ensure that our patients with difficult to treat diseases receive the best level of therapy in the future. Currently over 45 clinical trials are ongoing in the department, corresponding to over 20% of all studies performed at the Zurich University Hospital. It is our objective to continue strengthening our research activities, and to this end, 3 residents with academic potential were sent for fellowships abroad. We hope that such initiatives and the future establishment of endowed professorships will enable us to remain at the forefront of research and development in our field.

We are very happy and grateful for the continuous support and confidence that the hospital direction, the medical faculty of the University of Zurich, referring hospitals and referring physicians give us, and are confident that we can further develop this constructive collaboration.

I thank you for taking the time to review this report, which documents 2 years of wonderful contributions achieved by the faculty and staff of the department of dermatology of the University of Zurich.

In the name of the department of dermatology of the Zurich University Hospital,

Yours sincerely

Prof Lars E. French
Chairman
The Department of Dermatology of the Zurich University Hospital is devoted to provide sustained leadership in research, patient care and education in the fields of dermatology, venerology and allergology.

Our nationally and internationally recognized Department includes centers of excellence for skin cancer, inflammatory and allergic skin diseases and dermatological surgery. Within a team of 37 specialized physicians we offer high-level patient care in all areas of dermatology, venerology and allergology in the context of our large out-patient ambulatory care clinic (Dermatologische Poliklinik), our inpatient dermatology service, our day care unit, and tertiary care referral clinics in a large number of specialty areas. These include: melanoma and difficult pigmented lesions, non-melanoma skin cancers, cutaneous lymphoma, bullous and autoimmune skin disease, medical dermatology, psoriasis, hair and scalp disease, occupational and contact dermatitis, dermatologic surgery, dermatopathology, and physical therapies (phototherapy, radiotherapy and laser therapy).

Our research activities are focussed on basic and translational research with relevance to skin disease, focussing on skin cancer and inflammatory skin disease. The remarkable success of our research groups is reflected by regular high level publications and a high cumulative yearly impact factor. Collaboration and networking with talented scientists and research groups within the University of Zurich, the ETH, collaborative networks such as the Zurich Cancer network, and other leading European Dermatology Centers has amplified our research activities.

Education is the third principle field of activity of our Department - in the past few years, our Department has focussed its resources on pre- and post-graduate training as well as on the development and maintenance of an innovative internet-based pre-graduate learning tool—DOIT (Dermatology Online with Interactive Technology). In the coming years this program will be further developed into a European platform for online post-graduate education including online continuing medical education.
2. Mission Statement

The top priorities of the Department of Dermatology USZ – in close collaboration with other clinics and institutes of the USZ – are:

- to offer high quality individualized diagnosis and therapy of skin disease, as well as patient education in skin care and prevention of skin disease
- to provide a high level of teaching and training in dermatology at the pre- and post-graduate level
- to perform innovative basic and clinical research with the ultimate aim of contributing to improved patient-care
- to foster constructive collaboration and networks with private practitioners as well as primary and secondary institutional care providers

By fulfilling this mission we aim to position our department among the leading Dermatology Departments in Europe.
3. Team

The department of Dermatology has a staff of 160 people – including medical doctors, nursing staff, medical technical staff, laboratory staff, administrative staff, and 30 research collaborators.

Routinely, our Department hosts fellows and guests from abroad within its clinical and research activities.

**Staffing levels in 2008 according to occupation**

- Doctors/Other academic specialists: 17%
- Chairman: 7%
- Vice Chairman: 3%
- Associate Professors: 4%
- Senior Physicians: 3%
- Resident physicians: 4%
- Research collaborators (paid by external funding): 3%
- Nursing including medical technical radiology staff: 17%
- Laboratory technicians: 15%
- Administration: 10%
- Team of medical staff
  - Team of nursing staff
  - Team of secretaries/personal assistants
4. Patient Care

In the Swiss Health Service, inpatient dermatology is virtually exclusively available at the five university hospitals. In contrast, ambulatory care is offered both in the private sector and the public setting of university hospitals.

As the largest academic dermatology center in Switzerland, the Department of Dermatology at the University of Zurich offers an in-patient medical care for complex and rare skin problems. In addition we provide the most extensive spectrum of outpatient services including highly specialized consultations. Our department benefits from a large area referral base for these specialized activities as well as its own on-site histopathology laboratory.

Out-patient unit

In the general dermatology out-patient unit our teams mainly treat acute skin disorders and emergency cases mostly allergies, inflammatory disorders of the skin and skin infections. The most frequently treated skin diseases are eczema, psoriasis, «naevi» (moles), pigment disorders such as vitiligo, skin cancer and its precursors, as well as bacterial, viral or fungal skin infections.

In addition to our general dermatology outpatient service, our patients with specific skin diseases also have access to a number of specialized out-patient clinics:

- **Pigmented lesion clinic & skin cancer prevention:** In this consultation that runs under the direction of PD Dr. R. Braun, the latest high tech equipment (confocal microscopy, skin surface videomicroscopy, dermoscopy,total body imaging) is used for the early detection of melanoma.

- **Skin cancer unit (oncodermatology):** this consultation under the direction of Prof R. Dummer offers patients with skin cancer of different types (melanoma, lymphoma, squamous cell carcinoma of the skin, basal cell carcinoma and others) highly professionalized treatment and follow-up. A broad variety of treatments are available through this specialized and multidisciplinary consultation, including: surgical interventions, physical treatment with special light sources or radiotherapy, topical immunomodulatory treatments and chemotherapy. For patients with lymphoma, basal cell carcinomas and metastatic melanoma, several innovative therapies within the context of clinical trials are available.

- **Autoimmune skin diseases:** in this specialized consultation piloted by Prof R. Trueb, patients with diseases due to an overactive immune response and associated skin symptoms (autoimmune bullous diseases, dermatomyositis, scleroderma, lupus and others) benefit from expert advice, therapy and follow-up in a multidisciplinary setting.

- **Hair disorders (Trichology):** This consultation is directed by Prof R. Trueb who is internationally renowned for his expertise in this field, offering patients with complex hair disorders innovative treatment modalities.

- **Pediatric dermatology:** a dermatologic consultation service specialized for children and childhood skin disease, that is run in close collaboration with a board-certified pediatrician in our Department and the Childrens Hospital of the University of Zurich.

- **Psoriasis:** The management of this frequent skin disease has benefitted from the recent development of several new targeted medications – so-called “biologics”. Within this specialized consultation under the direction of Prof R. Trueb, patients can profit from the interdisciplinary nature of our expertise, our close collaboration with the Department of Rheumatology, our large panel of treatment modalities and innovative clinical trials.

- **Acne:** Our medical team under the direction of senior physician Dr. S. Läuchli (Oberarzt) offers – together with a dermatocosmetology specialist – expert advice in the management of acne and its cosmetic consequences.

- **Chronic wounds:** Patients with chronic venous leg wounds (ulcers), diabetic wounds, and ischemic arterial wounds amongst others have access in this consultation to a team of specialized nurses and MD’s under the direction of Prof J. Hafner, a double board-certified (Dermatology & Angiology) expert in the field.

- **Specialized consultations are also regularly held for hyperhidrosis, phlebology, urticaria and sexually transmitted diseases and proctology.**
Allergology Unit

The allergology unit of our department is a European certified (GALEN) center of excellence specialized in the diagnosis and treatment of acute and chronic allergic disease. Managed by PD Dr P Schmid and Prof B Ballmer-Weber, our allergy unit has developed a special focus on skin allergy, food allergy, drug al-lergy and desensitization protocols (specific immunotherapy), for example for life-threatening insect sting allergies.

Physical treatment unit – including irradiation-, phototherapy & laser unit

The department is equipped with the latest physical therapy technologies, including UVA1 devices and laser sys-tems. Recently, a modern X ray devices for superficial irradiation therapy have been purchased to help to continue the long standing tradition of this tolerated treatment option that is typically ap-plied for epithelial tumors in advanced age amongst others.

Day Care Clinics

Our day care clinic under the direction of PD Dr G Hofbauer provides a unique setting for the ambulatory provision of complex dermatological and/or systemic therapy by special-ized medical and nursing staff. Sequential treatments regimens under conditions of optimal compliance are frequently perfor-med in this setting for our patients with psoriasis and other autoimmune diseases, eczema, and infectious skin diseases for example. Extracorporeal phophopheresis, an immunomodulatory treatment for organ transplant recipients suffering organ rejection, and for cutaneous lymphoma patients is performed daily with our two photopheresis units in the day care clinic.

Surgery Unit

Our surgical unit and its experienced team of dermatological surgeons (Dr med S Läuchli and Prof J Hafner) have developed a renown activity in general dermatological surgery with a focus on skin cancer surgery and chronic wound surgery. Innovative techniques such as micrographic surgery (MOHS) for complex skin cancer cases, ablative laser treatments, or fibrotic tissue shaving and skin transplantation for complex wounds are re-gularly performed with a high level of patient satisfaction in this unit.

In-patient units D1, D2 & E2 (36 beds; of which 10 runned as «Wochenklinik» – Monday-Friday)

In our in-patient setting patients with severe inflammatory skin diseases (generalized eczema, psoriasis, autoimmune disor-ders), severe infectious skin disease, complex chronic wounds especially after a surgical intervention, and skin cancer patients

<table>
<thead>
<tr>
<th></th>
<th>2006</th>
<th>2007</th>
<th>Δ 2006 %</th>
<th>2008</th>
<th>Δ 2007 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Out-patients consultations</td>
<td>83'473</td>
<td>95'037</td>
<td>13.9 %</td>
<td>99'140</td>
<td>4.3 %</td>
</tr>
</tbody>
</table>

Consultations out patient-setting 2008

- Outpatient Unit
- Allergology Uni
- Epicutan-Test-Lab
- Radiation-Therapy-Unit
- Photo-Therapy-Unit
- Laser-Therapy-Unit
- Day Care Clinic
- "Persönliche Sprechstunde"
- Surgery Unit
requiring surgery or chemotherapy benefit of round the clock specialized care. The multidisciplinary nature of the medical and nursing team, the size and patient-flow, as well as the expertise of the senior medical staff responsible for the in-patient units (Prof L French, Prof R Dummer, Prof J Hafner, PD Dr G Hofbauer) make this an in-patient unit that is unique in its kind in Switzerland.

To be in line with an upcoming medical trend in dermatology, we reorganised part of the in-patient unit in 2007 so as to offer a «week-clinic» in which ten beds are solely operated from Monday to Friday. Our week-clinic matches the medical needs of a significant subset of our patients and referring physicians (intermittent in-patient care, short diagnostic work-ups, short in patient therapy) and is associated with a significant reduction in our overall mean length of inpatient hospital stay (7.9 days in 2007), but a higher workload for the staff due the high «patient turnover» and limited time-frame for diagnosis and care.

The main task of our nursing team is the care for patients suffering from oncologic diseases, chronic wounds and from severe autoimmune or allergic diseases – throughout all phases of the illness. Palliative care is also an important element of the spectrum of there responsibilities. Continuing nursing education in this challenging field assures the required highly professional experience and competence of the team.

In order to manage the continuing raising medical challenges regular intensive trainings on medical and nursing know-how are indispensable. Monthly clinic intern case report session as well as involvement in training activities of the Swiss Nursing Group Dermatology guarantees to maintain the presently high standard of quality of our nursing team (e.g. collaboration with «Wundexperten»).

Since several years the Department of Dermatology runs a CIRS (Critical Incident Reporting System) to ensure ambitious quality requirements.

As a multi-professional nursing team, it is our goal to help to build up a highly professional clinical and patient-oriented care in Dermatology. Therefore, we offer consulting to other care disciplines within the USZ and beyond.

---

### Dermatopathology

Essential for quality the main focus of our clinical activities

<table>
<thead>
<tr>
<th></th>
<th>2006</th>
<th>2007</th>
<th>Δ 2006 %</th>
<th>2008</th>
<th>Δ 2008 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsies</td>
<td>14'578</td>
<td>16'979</td>
<td>+ 16 %</td>
<td>20'042</td>
<td>+ 19.6 %</td>
</tr>
</tbody>
</table>

### Immunodermatology

- Center of Reference for Melanoma
- Center of Reference for Cutaneous Lymphoma
- MOHS (Micrographic Surgery of skin tumors)

---

### Dermat-o-ncology

- Center of Reference for Melanoma
  - Center of Reference for Cutaneous Lymphoma
  - MOHS (Micrographic Surgery of skin tumors)
**Laboratory setting**

The laboratory setting of the department includes fully equipped dermatopathology, allergology, mycology, serology/venerology and research laboratories.

As an essential tool for dermatological diagnosis and quality of patient care, our dermatopathology lab supervised by Prof R Dummer seconded by two senior dermatopathologists that are board-certified clinicians and dermatopathologists (Dr J Kamarascev, Dr K Kerl) performs histological diagnosis of approximately 19,000 skin biopsy samples per year. The importance of this laboratory is reflected by constantly rising referrals.

**Interdisciplinarity within USZ**

Several dermatologic disorders are associated with significant disease of other vital organs. Therefore intensive collaboration with other medical and surgical disciplines within the university hospital is daily practice.

**Key Financial Figures**

<table>
<thead>
<tr>
<th></th>
<th>2008</th>
<th>2007</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues (medical services)</td>
<td>26.4 Mio CHF</td>
<td>23.4 Mio CHF</td>
</tr>
<tr>
<td>Consultations out-patient setting</td>
<td>99'000</td>
<td>95'000</td>
</tr>
<tr>
<td>Patient entries in in-patient setting</td>
<td>1'236</td>
<td>1'143</td>
</tr>
<tr>
<td>(thereof 25% privately insured patients)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duration of stay</td>
<td>7.8 days</td>
<td>7.9 days</td>
</tr>
<tr>
<td>Occupation of inpatient beds (percent)</td>
<td>87%</td>
<td>85.6 %</td>
</tr>
<tr>
<td>Employees (full-time equivalents) (thereof 27 financed by third party funds)</td>
<td>160</td>
<td>160</td>
</tr>
</tbody>
</table>
5. Public Relations

We maintain regular and active information exchange with the public and private practitioners. Several communication channels are commonly used for this purpose and include interviews/commentaries in local and regional newspapers, regularly updated information and news on our website www.dermatologie.usz.ch, and a regular newsletter - in collaboration with the Zurich Dermatology Society - of «DermaZH».

In line with our focus on excellence in skin cancers, skin cancer prevention and early detection of skin cancer is a clear priority. High level prevention and early detection of skin cancer requires the transfer of information to the population and a continuous education effort for the population and physicians. In collaboration with the Swiss cancer league, regional cancer leagues, and the Swiss Society for Dermatology and Venerology we prepare and distribute printed and electronic information concerning skin cancer prevention and organise public events such as the yearly melanoma Monday (free melanoma screening day). Accordingly, the allergy department organizes «teaching evenings» for parents of children suffering from atopic eczema (neurodermitis) together with AHA (the Swiss patient organisation for atopic diseases).

6. Research Foundations

Our department promotes two charitable foundations aiming to support patient related high quality research:

- **The Bruno Bloch Stiftung** – founded in 1935 by the widow of Prof Bruno Bloch, Chairman of the Zurich Dermatology Department between 1916 and 1933; it supports skin research and education activities specifically in relation to the department of dermatology of the university of Zurich including research on chronic and severe skin diseases such as severe inflammatory illnesses and skin cancer.

- **The Association for Research of the Cancer of the Skin** (Verein für Hautkrebsforschung) [www.skincancer.ch] – founded in 2004 – aiming to coordinate and stimulate skin cancer research in Switzerland by supporting research in rare and severe forms of skin cancer (e.g. melanoma, cutaneous lymphoma). The board consists of several chairmen of Departments of Dermatology in Switzerland; it is currently chaired by Prof R Dummer. The current goal is to generate support for a professorship.
7. Research

Our aims for patient care such as the improvement of the quality of our services are critically dependent on innovation and thus research. Our department is committed to a high level of research in dermatology, and our achievement in this field – as judged by the cumulative impact factor for 2008 (355) – positions us amongst the leading Departments in the field.

The research activities of the Department of Dermatology are primarily focussed on basic, translational (patient-oriented), and clinical research in:

- dermato-oncology, concentration on pathogenesis, early diagnosis and molecular targeted treatment of skin cancer, particularly on melanoma, cutaneous lymphoma, and non-melanoma skin cancers.
- immunodermatology, especially innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis including the clinical study of targeted therapies, and severe allergic adverse drug reactions
- allergology, emphasizing on drug and food allergies, and specific immunotherapy

Key Figures and Highlights

- Currently 47 ongoing clinical trials of new therapeutic approaches in skin disease – corresponding to over 20% of all studies performed at the USZ
- 55 original and 21 review articles published in peer-reviewed journals in 2008
- Several high impact publications in the interdisciplinary journals
  - Hoek K et al.; In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res. 2008;68:650-6
- New intellectual property: in the last three years 4 patent applications have been submitted/registered.
- Promotion of academic renewal: 3 young clinician-scientists from our Department are currently performing fellowships in leading academic centers in the United States.

Aim of our research activities

- promote high quality research with clinical relevance in the defined above mentioned fields of focus
- intensive networking and collaboration with other institutes and departments at the Zurich University and ETH, as well as through active participation in networks such as the «cancer network Zurich»
- support fellowships abroad in excellent research institutions of the Swiss National Science Foundation (incl. SCORE A career development awards or SNF professorships)
- two endowed professorships in our Department in inflammatory skin disease and skin cancer research respectively, with the aim of recruiting or retaining leaders in these research fields to our department
Research Groups

Group Members
Prof Barbara Ballmer-Weber
(group leader)
Dr med Christoph Metzler
Dr med Peter Bures
Dr med Stefanie Christensen
Irène Cuhat

Main Fields of Research
Our research activities are focused on food allergy, in particular pollen related food allergy. We are particularly involved into the identification and molecular characterisation of important cross-reactive allergens, and the development of diagnostic and therapeutic methods based on recombinant allergens. Another important aspect of our research activity is risk assessment in food allergy in regard to genetic modified foods/novel foods but also threshold doses (minimal allergen doses to induce an allergic reaction) of plant and animal food allergens.

Selected References

Group Members
Dr sc nat Philipp P Bosshard
(group leader)

Main Fields of Research
Our research activities focus on (i) sexually transmitted diseases (e.g. development and evaluation of molecular methods for etiologic diagnosis), (ii) fungal infections (e.g. optimization of diagnostic procedures)

Selected References
**Group Members**

**PD Dr Ralph Braun (group leader)**

Dr med Isabelle Kolm

**Main Fields of Research**

Our main interest is non invasive diagnosis of skin cancer especially malignant melanoma. We use established techniques such as dermoscopy as well as new techniques in vivo laser scanning microscopy, dermoscopy. Due to different international research collaborations our patients benefit directly from the latest technological developments. Detecting skin cancer especially melanoma at early stages offers an unique opportunity because if diagnosed early enough skin cancer can be cured.

**Selected References**


---

**Group Members**

**PD Dr med + Dr sc nat Antonio Cozzio (group leader)**

Dr med Joanna Mangana
Mirka Schmid

**Main Fields of Research**

Cancer stem cells represent an emerging field for cancer research because of the increasing evidence that such cells, even though rare within a tumor, have the capacity to sustain tumor formation and regeneration. Both Melanoma and Merkel cell carcinoma are derived from cells with neurocrest origin, i.e. the melanocytes and Merkel cells. We are addressing the presence of cancer cells with neural crest stem cell features in these tumours (Collaboration with R. Dummer, MD, Dermatology, Zurich). Sézary syndrome is a subgroup of cutaneous T cell lymphoma with leukaemic features and a poor prognosis. In analogy to the above-mentioned project, we are trying to define population subsets with diverse biologic properties (e.g. in terms of self renewal capacity).

**Selected References**

Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO/EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome. Leuk Lymphoma. 2008 Jun;49(6):1094-103.


---

**Group Members**

**Prof Reinhard Dummer (group leader)**

Marjam Barysch, MD
Christa Dudli, Technician
Ossia Eichhoff, Ph.D. Student
Keith Hoek, Postdoc
Simone Goldinger, MD
Maria Karpova, Postdoc
Elisabeth Laine, Technician
Eva Sailer, MD
Marie Zipser, MD
Daniel Widmer, Ph.D. Student

**Main Fields of Research**

We have intensively studied the immune biology of cutaneous lymphomas, cutaneous melanoma and epithelial skin cancers. Based on the microenvironment of these tumors, we have established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to our patients in order to provide effective treatment with best quality of life.

**Selected References**


Group Members
Prof Lars E French (group leader)

Dr Emmanuel Contassot (PI, PhD)
Dr Magdalena Kistowska, PhD
Gehrke Samuel, PhD student
Marianne Spalinger, technician
Maria-Jesus Pena-Rodriguez, technician
Nikita Kober, technician

Main Fields of Research
Our group is focussed on understanding the role of death receptor-mediated apoptosis, as well as danger- and pathogen sensing via the IL-1b-processing inflammasome platform in the pathogenesis of inflammatory skin disease and skin cancer.

Our current research projects include: 1) the study of the role of inflammasome in skin cancer and graft versus host disease; 2) the study of the mechanisms of apoptosis resistance in cutaneous T cell lymphoma; and 3) the study of the pathways leading to keratinocyte cell death in severe adverse cutaneous drug reactions.

Selected References


Name of the Group Leader
PD Dr med Schmid-Grendelmeier

Name of the Institution
Allergy unit, Dept. of Dermatology, University Hospital of Zurich

Group Members
Dr med Christian Bull
Dr med Tina Gottschaller
Dr med Meike Distel
Sabine Zeller, PhD student (SIAF Davos)
Suzanne Marti-Wyss

Main Field of Research
The main fields of our research are
- the elucidation of the molecular and immunologic mechanisms underlying atopic dermatitis, especially autoimmune phenomena due to molecular mimicry with microbes including also tropical settings
- improved methods of allergen-specific immunotherapy
- the establishment of new treatment modalities for mastocytosis and C1-Inhibitor deficiency
- the interaction between pollution and prevalence of atopic diseases within the SAPALDIA cohort (Swiss Study on Air Pollution and Lung Diseases in Adults)

Selected References

Name of the Group Leader
PD Dr med Schmid-Grendelmeier

Name of the Institution
Allergy unit, Dept. of Dermatology, University Hospital of Zurich

Group Members
Dr med Christian Bull
Dr med Tina Gottschaller
Dr med Meike Distel
Sabine Zeller, PhD student (SIAF Davos)
Suzanne Marti-Wyss

Main Field of Research
Our research activities are focused on clinical trials with biologics in the treatment of psoriasis and for dermatologic off-label indications; the study of autoimmune diseases (collagen vascular diseases, autoimmune bullous diseases, vasculitis) with a special interest in novel diagnostic procedures and treatment strategies; and the study of hair and hair disorders, with a particular interest in inflammatory phenomena, diffuse hair loss in women, environmental factors, hair care, patient expectation management, hair aging and anti-aging.

Selected References
8. Medical Education / Teaching

Medical education is crucial to guarantee a high level of professionalism of physicians and other health care professions. Our continued implication in education is reflected by

1. Education of students in the medical faculty of the university
2. Specialty Training in Dermatology of resident physicians for board-certification in «Dermatology», and in «Allergology and Immunology» for residents board certifying in allergology and clinical immunology
3. Continuing medical education of private practitioners — mainly dermatologists and allergologists, but also general practitioners and to a lesser extent other health care professions.

Education for students: Senior physicians of our department provide an introductory course for dermatology to 3rd year medical students, a yearly core course in dermatology (8-day Themeblock) to 4th year medical students, repetitory lectures in both, dermatology and allergology in the 6th year and a practical training course in dermatology in the 6th year.

In complement to these ex-cathedra and bed-side teaching activities, medical students web-based learning using an online platform (DOIT: Dermatology Online with Interactive Technology) developed by the former Chairman of our department (Prof Dr med Dr h. c. Günter Burg) in a close collaboration with several other dermatology departments (Basel, Bern, Lausanne, Jena and Stadtspital Triemli in Zurich). This platform is being continuously improved and currently exists in six languages and two further languages are scheduled.

Resident physicians: The Department of Dermatology offers 22 residency positions for the 5 years of training that are required for swiss board certification in dermatology. Demand for residency training in our department is extremely high, with more than 150 applications for approximately 4 available positions per year. 2 training positions are also available for part of the board certification in immunology and allergology, as well as that of angiology. During their residency training in our department, residents benefit of the broadest offer in Switzerland, comprised of a rotation plan through 20 stations covering all subspecialties of dermatology and allergology, including dermatoncology, autoimmune skin disease, trichology (hair disease), dermatosurgery, dermatopathology, physical skin treatments (radiotherapy, UV-therapy, laser), phlebology and others.
Following interest from the German, Austrian and Swiss dermatological societies, the online platform for students (DOIT) is now being used as the base for the development of a pan-European post-graduate online continuing medical education (CME) platform.

**Continuing medical education (CME)/Postgraduate training for private practitioners**

Our Department and Faculty offer 12–14 CME events and grand rounds per year – 6 half-day thematic CME events per year in the University Zurich Irchel (180-200 participants), and 6-8 grand rounds and interdisciplinary CME sessions, the latter co-organized with other medical disciplines at USZ. In addition to this, and as of 2007, 4 new CME’s per year entitled «Dermatology Update» have been added to our postgraduate teaching program, with the aim of providing a further platform for case presentations, short updates and an overview of important new publications in dermatology (Journal Club).

**Overview 2007 and 2008**

**Continuing medical education 2007**

<table>
<thead>
<tr>
<th>Subject/Title</th>
<th>Type of education</th>
<th>Date</th>
<th>Responsible physician for organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Journal Club Allergy</td>
<td>Journal Club</td>
<td>March, 22, 2007</td>
<td>Dr Th Harr</td>
</tr>
<tr>
<td>Haut-Psoriasis – auch eine interdisciplinäre Herausforderung</td>
<td>Interdisciplinary</td>
<td>March 29, 2007</td>
<td>Prof Dr R Trüeb et al</td>
</tr>
<tr>
<td>Hauttumore</td>
<td>Update/Journal Club*</td>
<td>April 12, 2007</td>
<td>Prof Dr L French</td>
</tr>
<tr>
<td>Allergie und Asthma</td>
<td>Interdisciplinary</td>
<td>May 3, 2007</td>
<td>PD Dr P Schmid-Grendelmeier</td>
</tr>
<tr>
<td>AAD Update on Biologics</td>
<td>Update/Journal Club*</td>
<td>May 10, 2007</td>
<td>Prof Dr R Trüeb</td>
</tr>
<tr>
<td>Vitiligo</td>
<td>Irchel</td>
<td>May 31, 2007</td>
<td>Prof Dr R Trüeb</td>
</tr>
<tr>
<td>STD Update</td>
<td>Update/Journal Club*</td>
<td>June 14, 2007</td>
<td>PD Dr G Lautenschlager</td>
</tr>
<tr>
<td>Update Neurodermitis</td>
<td>Update/Journal Club*</td>
<td>October 11, 2007</td>
<td>PD Dr P Schmid-Grendelmeier, Prof Dr L French</td>
</tr>
<tr>
<td>Schmerz- und Palliativ-Therapie bei dermato-onkologischen und Ulcus-Patienten</td>
<td>Interdisciplinary</td>
<td>October 25, 2007</td>
<td>Prof Dr R Dummer, Prof Dr J Hafner, Prof Dr L French</td>
</tr>
<tr>
<td>Dermatologisch-Allergologischer Kurs S GDV</td>
<td>S GDV-Kurs</td>
<td>October 25/26 2007</td>
<td>Prof B Ballmer-Weber, PD Dr P Schmid-Grendelmeier</td>
</tr>
<tr>
<td>Interaktive Fortbildung zu pigmentierten Hautveränderungen – Testen Sie Ihr Fachwissen</td>
<td>Irchel</td>
<td>November 8, 2007</td>
<td>Prof Dr R Dummer</td>
</tr>
<tr>
<td>Urticaria</td>
<td>Irchel (together with Basel and Berne)</td>
<td>November 11, 2007</td>
<td>Prof Dr B Ballmer-Weber</td>
</tr>
<tr>
<td>Differentialdiagnose und Therapie von Mundschleim-Hauterkrankungen</td>
<td>Interdisciplinary (with Stomatology)</td>
<td>November 22, 2007</td>
<td>Prof Dr R Trüeb, Prof Dr Krätz</td>
</tr>
<tr>
<td>Update Warzen und Kondylome</td>
<td>Update/Journal Club*</td>
<td>December 6, 2007</td>
<td>PD Dr W Kempf, Prof Dr L French</td>
</tr>
</tbody>
</table>
In addition to regular postgraduate teaching, our department organizes national and international symposia and/or congresses. A highlight in 2007 was the 37th Annual Meeting of the European Society for Dermatological Research (ESDR), chaired by Prof Dr Reinhard Dummer for our Department, that attracted 1000 participants from the whole world.

In 2009, we have organized the Spring Meeting of the SGDV (= Swiss Society for Dermatology and Venerology) an in 2010 the Annual Meeting of the SGDV at Zurich University.
<table>
<thead>
<tr>
<th>Guest Speakers 2007 and 2008</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bachmann Martin</td>
<td>PD Dr</td>
<td>Cytos Biotechnology Vaccination against chronic diseases</td>
</tr>
<tr>
<td>Bruckner-Tuderman Leena</td>
<td>Prof Dr med</td>
<td>Universität-Hausklinik Freiburg, Deutschland</td>
</tr>
<tr>
<td>Eming Rüdiger Dr</td>
<td>Dr med</td>
<td>Klinik für Dermatologie und Allergologie, Universtätsklinik Marburg</td>
</tr>
<tr>
<td>Fuchs Thomas</td>
<td>Prof Dr med</td>
<td>Georg-Augustus-Universität Göttingen, Deutschland</td>
</tr>
<tr>
<td>Giefer Uwe</td>
<td>Prof</td>
<td>Institut für Medizinische Psychologie, Justus-Liebig Universität Gießen, Deutschland</td>
</tr>
<tr>
<td>Hauser Conrad</td>
<td>Prof</td>
<td>Div. Immunol. and Allergy, Dept. Int. Medicine, University of Geneva</td>
</tr>
<tr>
<td>Klimek Ludger Prof Dr</td>
<td>Dr med</td>
<td>FA Orl. and Allergologie, Wiesbaden, Deutschland</td>
</tr>
<tr>
<td>Koschel Dirk</td>
<td>Dr med</td>
<td>LA Inner Medizin-Pneumologie, Fachkrankenhaus Cossig, Deutschland</td>
</tr>
<tr>
<td>Lambeck Martin</td>
<td>Prof Dr</td>
<td>Technische Universität Berlin</td>
</tr>
<tr>
<td>Marghoob Ashfaq</td>
<td>Assistant Professor</td>
<td>Memorial Sloan Kettering Cancer Center</td>
</tr>
<tr>
<td>Meerang Mayara Dr</td>
<td>Dr</td>
<td>German Cancer Research Center Heidelberg, Deutschland</td>
</tr>
<tr>
<td>Sennekamp Joachim</td>
<td>Prof Dr med</td>
<td>FA Internist und Allergologie, Bonn, Deutschland</td>
</tr>
<tr>
<td>Spiewak Radoslaw</td>
<td>Prof Dr med</td>
<td>Krako, Deutschland</td>
</tr>
<tr>
<td>Thilo Jakob Prof Dr med</td>
<td>Dr</td>
<td>Universität-Hausklinik Freiburg, Deutschland</td>
</tr>
<tr>
<td>Weisenseel Peter</td>
<td>Dr med</td>
<td>Klinik und Praklinik für Dermatologie und Allergologie, Klinikum der Universität München</td>
</tr>
<tr>
<td>Wymann Matthias</td>
<td>Prof</td>
<td>Center for Biomedicine, Universität Basel</td>
</tr>
</tbody>
</table>

**Bigliardi Paul**
- PD Dr
- CHUV Lausanne
- Pruritus: Ursachen und Behandlung

**Bircher Andreas Prof Dr**
- Universitätsspital Basel
- Medikamentenallergie

**Breather Lasse Prof Dr**
- Inselspital Bern
- operative Therapie der Vitiligo: Autologer Melazententransfer

**Brezna Irena**
- Psychologin, Schriftstellerin
- Basel
- Psychologische Aspekte der Poräisie

**Brüning Martin Dr**
- Inselspital Bern
- pharmakotherapie der Vitiligo

**Böhm Markus**
- PD Dr
- Universitätsklinik München
- Pathobiologie der Vitiligo

**Calascia Thomas Dr**
- University of Toronto
- Boosting T cell immunity to cancer and chronic viral infections using IL-7 therapy

**Dupuis Marc**
- PhD Preclinical Oncology
- Apoxis SA, Lausanne
- The effects of the anticancer drug APO866 in a mouse model of cutaneous T cell lymphoma

**Escher Niko**
- Dipl. Biol.
- Universitätsklinik Jena
- Mass spectrometry based proteomic profiling of cutaneous t-cell lymphoma (ctl)

**Ettlin Dieter Dr**
- Klinik Birchl Münchenstein
- Burning mouth-Syndrom: Funktionell oder somatisch?

**Gebhardt Christoffer Dr**
- University Heidelberg
- How RAGE feeds the flame - a novel mechanism in cancer development. 5100 review (Science)

**G rattan Clive Prof Dr**
- Norfolk and Norwich University Hospital NHS Trust, UK
- Management and Therapie der Urtikaria

**Grob Jean-Jacques Prof Dr**
- Hôpital Ste Marguerite, Marseille
- Therapy with Interferon – A 20 year experience

**Hauser Conrad Prof Dr**
- Hôpital Universitaire de Genève
- Management der Urtikaria

**Il ten Peter Prof Dr**
- Universitätsspital Basel
- Differentialdiagnose depigmentierender Hauterkrankungen

**Locher Michael Dr**
- Praxis Waldshut-Tiengen
- Diagnose und Therapie des oralen Lichen planus

**Luczky Monika PhD**
- Transgene France
- Gene therapy using adenoviral vectors

**Mauviel Alain Prof Dr**
- Hôpital Saint Louis Paris
- New targets of TGF-β: implications for melanoma progression and metastasis

**Mempe1 Martin Prof Dr**
- Technische Universität München
- The B-cell repertoire in highly atopic patients

**Novak Natalija PD Dr**
- Universitätsspital Bonn
- Neurodermitis - ein Update

**Piguet Vincent Prof Dr**
- University Hospital of Geneva
- Interactions between HIV and dendritic cells and OATAS analysis of melanoma

**Rast Hanspeter Dr**
- SUVA Luzern
- Begutachtung und Entschädigung von Berufsdarmonen

**Ruffner Heinz**
- Group leader cell biology
- Cellbase AG Heidelberg
- Physical and functional mapping of signal transduction pathways

**Schadendorf Dirk Prof Dr**
- Deutsches Krebsforschungszentrum Heidelberg
- molekularbiologie des Melanoms – Was ist klinisch relevant?

**Scherer Kathrin Dr**
- Universitätsspital Basel
- Die urtiakaliene Acnemeintheilaktion

**Schnei Merkel Prof Dr**
- Institut der Georg-August-Uni. Göttingen
- Nickel, Dürre, Kleber & Co. Welche Kontaktallergene sind wichtig?

**Schönbächler Georg Dr sc. nat.**
- Collegium Helveticum
- Plazemo - die Apotheke im Kopf

**Simon Dagmar PD Dr**
- Inselspital Bern
- Urtikaria: welche Differentialdiagnosen sind möglich?

**Weidinger Stephan Dr**
- Technische Universität München
- Filaggrin mutations and epidermal barrier integrity
9. Partners / Sponsors / Collaborations with Industry and Fund Raising (private industry)

Our continuous efforts in medical education, public relations, marketing, and networking with private practitioners is only possible thanks to external funding. We collaborate with industry for our postgraduate education, giving private practitioners and industry a platform for communication and exchange. Furthermore, possibilities are provided by our charitable foundations the Bruno Bloch Stiftung and the Verein für Hautkrebsforschung. We would here like to acknowledge with great respect the support of our industrial partners. Their collaboration supports the quality and nature of our postgraduate teaching offer.

The Department of Dermatology USZ is grateful to the following sponsors and donators for their constant precious and generous support.

With special acknowledgement to our partners of «Schwerpunkt Hautkrebs»
Cosmétique Active, Schweiz AG (LaRoche-Posay, Laboratoires Vichy)
Galdema S.A.
Roche Pharma (Schweiz) AG

«Kosmetische Dermatologische Sprechstunde»
Beiersdorf AG (Eucerin)
Leo Pharmaceutical Products SA
Louis Widmer AG
Merz Pharma (Schweiz) AG
Permamed AG
Pierre Fabre (Suisse) SA, Avène
Spirig Pharma AG

Further sponsors:
Abbott AG
Actelion (Schweiz) AG
ALK Abello
Allergomed AG
Allmiral AG
Astellas Pharma AG
AstraZeneca AG
Bank Julius Bär AG
Bauerfeind AG
Bayer (Schweiz) AG
Biotest AG
Bristol-Myers Squibb AG
Coloplast AG
CSL Behring (Schweiz) AG
Dermapharm AG
Drossa Pharm AG
Essex Chemie AG
Ganzoni & Cie AG
Gebro Pharma AG
Geistlich Pharma AG
Glaxo Smith Kline AG
J.-P., F. & E. Hottinger & Co., Effektenhändler
IBSA Institut Biochimique SA
Johnson & Johnson Medical
Meda Pharma Pharma GmbH
Merck Sharp & Dome AG
Mundipharma Pharmaceutical Company SA
Novartis (Schweiz) AG
Pfizer AG
Qualicare AG
MerckSerono (Pharma) Schweiz
Servier (Suisse) SA
Smith & Nephew AG
Teomed AG
Trimedal AG
Waldmann Lichttechnik GmbH
Wyeth Pharmaceuticals AG
Valucept
Charitable institutions closely associated with the Department of Dermatology USZ

Bruno Bloch Stiftung
Sekretariat:
Dermatologische Klinik, Direktion
UniversitätsSpital Zurich
Gloriastrasse 31
8091 Zurich
brunoblochstiftung@usz.ch

Bankverbindung:
UBS AG
8091 Zurich
Konto-Nummer 206-P0238697.0
Kennwort «BrunoBlochStiftung»

Verein für Hautkrebsforschung
Sekretariat:
Dermatologische Klinik
UniversitätsSpital Zurich
Gloriastrasse 31
8091 Zurich
info@skincancer.ch, www.skincancer.ch

Bankverbindung:
Jean-Philippe, François & Emmanuel Hottinger & Co.,
8091 Zurich
Effektenhändler, Zurich
Bank: Clariden Leu AG, Zurich, Swift: CLECHZZ
Begünstigter: Verein für Hautkrebsforschung
Konto CHF: IBAN: CH77 0506 5024 9124 3100 0
10. Honors and Prizes

**Prof Dr B Ballmer-Weber**
- Nomination to the Food Allergy Group of the World Allergy Organisation in spring 2007
- Election as Member of the Board of Foundation of the «Allergiestiftung Müller-Gierok» in autumn 2008

**Dr C Conrad**

**PD Dr A Cozzio (& Prof Dr R Dummer)**
- Promotion of a Research Project of an interdisciplinary project of the Swiss Cancer League «Neuralleisten-Stammzellen bei Hauttumoren» with participation of PD Dr A Cozzio and Prof Dr R Dummer

**Prof Dr R Dummer**
- Election as President of the ISCL (International Society for Cutaneous Lymphoma) in September 2006
- Election to the Board of the ICDP (International Committee for Dermatopathology) in spring 2007
- Election as President the ESDR (European Society for Dermatological Research) in October 2008
- Nomination to International Member of the Scientific Board of the ÖGDV (Austrian Society of Dermatology an Venerology) in Autumn 2008

**Prof Dr L French**
- Nomination as Member of the «Deutsche Akademie der Naturforscher», Leopoldina, in September 2008
- Election to the Executive Committee of the EDF (European Dermatology Forum) in January 2007

**Dr M Geiges**
- Nomination to Corresponding Member of the ÖGDV (Austrian Society of Dermatology an Venerology) in January 2008
- Election as Secretary-Treasurer of the ESHDV (European Society for the History of Dermatology/Venerology) in September 2008

**Dr Th Harr**
- Election as Board Member of the Swiss Society for Aerobiology in spring 2008

**Prof Dr J Hafner**
- Nomination as Member of the FMCH (Foederatio Medicorum Chirurgorum Helvetica) and as Member of the Board for the section «Fort- und Weiterbildung»

**PD Dr G Hofbauer**
- Nomination as Representative for Dermatology to the Directory of the new founded Transplant Center of the University Hospital Zurich in December 2007
- Election as Board Member and Secretary of the European Association in the coaching of organ transplanted patients (SCOPE) in April 2008

**Dr J Kamarachev**
- Certification of the «International Committee for Dermatopathology (ICPD-UEMS)» in December 2006

**Prof Dr W Kempf**
- Robert-Fischer-Prize for scientific work on cutaneous lymphoma in 2007

**Dr K Kerl**
- Certification of the «International Committee for Dermatopathology (ICPD-UEMS)» in December 2008

**Dr S Läuchli**
- Election to the Board of EWMA (European Young Management Association) as only Representative of German-speaking countries

**Dr J Mangana**
- Greek (Research Group of Prof Dr R Dummer)
- Dr Janssen Scholarship Award in August 2008

**PD Dr P Schmid-Grendelmeier**
- Election as Corresponding Member to the Board and Swiss Representative for Elaborating Guidelines for Neurodermatitis and Specific Immunotherapy of the German Society of Allergology and Clinical Immunology

**Prof Dr R Trüeb**
- Election as President of the EHRS (European Hair Research Society) in autumn 2008

**PD Dr M Maiwald-Urosevic**
Dr L Weibel
- Ruggero Caputo Young Pediatric Dermatologist Prize of the ESDP (European Society for Pediatric Dermatology)

Allergy-Unit
(chaired by Prof B Ballmer-Weber & PD Dr P Schmid-Grendelmeier)
- Quality Certification GA2LEN network (global allergy & asthma European network) as first center in Europe, in January 2007
- Election to «Center of Excellence» into the European Competence Network for Mastocytosis in spring 2008

Promotions since 2007
- Prof Dr B Ballmer-Weber:
  promotion to title of «Titularprofessur» in 2008
- Prof Dr R Dummer:
  promotion to title of «Professor ad personam» in 2008
- Prof Dr J Hafner:
  promotion to title of «Titularprofessur» in 2007
- Dr Th Harr:
  Promotion to title of «Oberarzt» in 2008
- PD Dr G Hofbauer:
  Promotion to title of «Leitender Arzt» in January 2009
Interview with Prof Dr med Lars French, Chairman, Department of Dermatology USZ

The Clinic Report of the Zurich University Hospital’s Department of Dermatology highlights the broad spectrum of activities in patient care, research and teaching. What are your priorities and important goals for the near future?

French: It is our final aim to be among the best Dermatology Departments with respect to patient care and research; this ambitious vision can only be achieved by defining clear priorities. For me outstanding quality in patient care and innovation are the top priorities of the Department.

The patient is in the center. Quality is a top priority.

What about research – in an internationally oriented Dermatology Department such as Zurich?

Research in an interdisciplinary environment with open-minded interactions with basic research institutions are in my opinion essential prerequisites for innovation. Priority topics in our Department are currently skin cancer, strongly focussed on melanoma, the mechanisms of skin inflammation with main focus on psoriasis. Internationally, our department is intergraded in the line of leading institutions for their contribution to innovation in Dermatology through research. It is also regularly visited by scholars, fellows, as well as renown scientists and physicians with the aim of fostering exchange, testifying its international attractiveness.

In the patient’s view, a frequent concern is the long time it usually takes until they can directly benefit from research?

This is generally correct. The complexity of diseases such as melanoma; the regulatory constraints that govern patient-oriented and clinical research today; as well as the time from discovery to completed drug development make therapeutic innovation an long process. However, a look back at novel therapeutics and their impact in our field over the last 5 years, clearly puts this into perspective. Despite the above hurdles, the quality of dermatological research including patient-oriented or translational research; the contribution of improved technology; and the close collaboration with industrial partners is now providing more innovative therapy than ever before. In this context, it is also possible for our patients to have access to novel therapeutics through clinical trials before they are marketed.

Rapid translation of patient-oriented research from the laboratory to the clinic, and collaboration with industry - play a key role in rapidly bringing new therapeutics to our patients.

You mention «quality» as a descriptive keyword for the Department. Are there already concrete measures that have been realized to assure this?

Yes, we started implementing quality assurance in the beginning of 2007 by introducing a Critical Incident Reporting System (CIRS) in our Department; this tool allows our staff – doctors and nurses – to report critical situations anonymously even if no detrimental consequences of the incident occurred. Such reports are regularly evaluated and used to implement strategies to avoid such situations in the future.

Do you have an internationally renown quality certification?

No, but this is an aim of ours. We are currently preparing for an international quality certification. This is primordial for us, especially in dermatooncology where recognition as a multidisciplinary skin cancer center requires ISO- or KTQ-Certification (= Cooperation for Transparency and Quality in Health Care) of the center.

International quality management labelling is important for future development.

Besides official quality certification measures, what measures have you undertaken in order to optimize the department after your onset as Chairman?

We have significantly reorganized the Department to adapt it to our aims; current patient needs; the number of employees; and upcoming regulatory requirements. This reorganization has lead to clear redistribution and definition of competences and responsibilities as required for the activities of our Department. This is illustrated in part through our new organigram.
Back to research: Do you also plan to reorganise certain aspects of this field of activity?

We will continue the focus of our research activities; dermatology, immunodermatology and allergology; subspecialties of Dermatology where demand for innovation in patient care is very high. The level of yearly funding obtained by researchers in the department is quite high for European standards (over 3 mio CHF/year), and alongside the current cumulative yearly impact factor of 324, a sign that our research groups are competitive and productive.

How will you ensure long-term competitiveness?

I have set a priority on supporting young skilled clinicians interested in science and an academic career. In the last two years three of our residents have had the opportunity to join prominent research groups abroad for a postdoctoral or clinical fellowship. I intend to support those who are motivated and successful for fellowships abroad and — if possible — for reintegration in our Department upon return. We are also in the process of building new endowed professorships at the Department to attract qualified researchers. Such activities should help guarantee long-term competitiveness.

Teaching – are there any new concepts that you envisage to implement in Zurich?

We are committed to the process of further implementing and improving an innovative, interactive internet-based learning-program (DOIT: Dermatology Online with Interactive Technology) founded by my predecessor, Prof Günter Burg. In Switzerland, the tool is already regularly used for teaching of students; presently is being further developed in collaboration with the Swiss, German and Austrian Societies for Dermatology, as a European internet-based platform for continuous medical education in dermatology.

And back to — according to your own words — the core activity of the Department of Dermatology — patient care: Why is Zurich able to offer such a diverse and high quality level of medical care in Dermatology?

For me, in Zurich, the strong support of the medical faculty the University of Zurich and of the University Hospital; the size and level of training of the medical team; as well as the extremely well developed inter-disciplinary network of specialists of other clinics and institutes are the ingredients that enable us to offer a high level of medical care.
12. Publications

Publications 2007

Original papers (peer-reviewed)


Bowling, J; Argenziano, G; Azenha, A; Bandic, J; Bergman, R; Blum, A; Cabo, H; Di Stephani, A; Grichnik, J; Halpern, A; Hofman-Wellenhof, R; Johr, R; Kuller, H; Kopf, A; Kreusch, J; Langford, D; Malvehy, J; Marghoob, A; Menzies, S; Ozdemir, F; Peris, K; Piccolo, D; Pizzichetta, MA; Polsky, D; Puig, S; Rabinovitz, H; Rubegni, P; Saida, T; Scalvenzi, M; Seidenari, S; Soyer, HP; Tannah, M; Zalaudek, I; Braun, RP (2007): Dermoscopy key points: recommendations from the international deroescopy society. In: Dermatology 214(1), 3-5


Braun, RP; Baran, R; Le Gal, FA; Dalle, S; Ronger, S; Pandolfi, R; Gaide, O; French, LE; Laugier, P; Saurat, JH; Marghoob, AA; Thomas, L (2007): Diagnosis and management of nail pigmenations. In:

Journal of the American Academy of Dermatology 56(5), 835-47

Braun, RP; Gaide, O; Le Gal, FA; Saurat, JH; Marghoob, AA (2007): [Follow-up of melanoma lesions]. In: Revue médicale suisse 3(109), 1119-23

Braun, RP; Gaide, O; Olivierio, M; Kopf, AW; French, LE; Saurat, JH; Rabinovitz, HS (2007): The significance of multiple blue-grey dots (granularity) for the dermoscopic diagnosis of melanoma. In: The British journal of dermatology 157(5), 907-13

Braun, RP; Gaide, O; Skaria, AM; Kopf, AW; Saurat, JH; Marghoob, AA (2007): Exclusively benign dermoscopic pattern in a patient with acral melanoma. In: Archives of dermatology 143(9), 1213-5; author reply 1215-6

Changchien, L; Dusza, SW; Agero, AL; Korzenko, AJ; Braun, RP; Sachs, D; Usman, MH; Halpern, AC; Marghoob, AA (2007): Age- and site-specific variation in the dermoscopic patterns of congenital melanocytic nevi: an aid to accurate classification and assessment of melanocytic nevi. In: Archives of dermatology 143(8), 1007-14


Marghoob, AA; Korzenko, AJ; Changchien, L; Scope, A; Braun, RP; Rabinovitz, H (2007): The beauty and the beast sign in dermoscopy. In: Dermatologic surgery 33(11), 1388-91


Marghoob, AA; Korzenko, AJ; Changchien, L; Scope, A; Braun, RP; Rabinovitz, H (2007): The beauty and the beast sign in dermoscopy. In: Dermatologic surgery 33(11), 1388-91


Mnih CD, Hoek KS, Oberholzer PA, Seifert B, Hafner J, Dummer R, Miähic D (2007): Reduced pSmad2 immunodetection correlates with increased primary melanoma thickness In: Melanoma research 17, 131-136


Perrinaud, A; Gaide, O; French, LE; Saurat, JH; Marghoob, AA; Braun, RP (2007): Can automated dermoscopy image analysis instruments provide added benefit for the dermatologist? A study comparing the results of three systems. In: The British journal of dermatology 157(5), 926-33


Scope, A; Busam, KJ; Malvehy, J; Puig, S; McClain, SA; Braun, RP; Marghoob, AA (2007): Ex vivo dermoscopy of melanocytic tumors: time for dermatopathologists to learn dermoscopy. In: Archives of dermatology 143(12), 1548-52

Scope, A; Tabanelli, M; Busam, KJ; Rabinovitz, H; Braun, RP; Marghoob, AA (2007): Dispelling the myth of the “benign hair sign” for melanoma. In: Journal of the American Academy of Dermatology 56(3), 413-6


Book chapters and books


Publications 2008

Original papers (peer-reviewed)


Bernier, J; Bonner, J; Vermorken, J B; Bensadoun, R J; Dummer, R; Giralt, J; Kornek, G; Har tley, A; Reske, S; Serafetinides, E; Ang, K K; Hartley, A; Reske, S; Serafetinides, E; Ang, K K (2008): Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. In: Annals of Oncology 19(1), 142-149 http://dx.doi.org/10.1093/annonc/mdm400

Braun, R P; Thomas, L; Kolm, I; French, L E; Marghoob, A A (2008): The furrow ink test: a clue for the dermoscopic diagnosis of acral melanoma vs nevus. In: Archives of Dermatology 144(12), 1618-1620 http://dx.doi.org/10.1001/archderm.144.12.1618

Contassot, E; Kerl, K; Roques, S; Shane, R; Gaide, O; Dupuis, M; Rook, A H; French, L E (2008): Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezar y syndrome T-cells associated with impaired death receptor and FasL-inhibitor y protein expression. In: Blood 111(9), 4780-4787 http://dx.doi.org/10.1182/blood-2007-08-109074

Dissanayake, S K; Oikhanud, P B; O’Connell, M P; Car tet, A; French, A D; Camilli, T C; Emeche, C D; Hewitt, K J; Rosenthal, D T; Leotlela, P D; Wade, M S; Yang, S W; Brant, L; Nicoloff, B J; Messina, J L; Biragyn, A; Hoek, K S; Taub, D D; Longo, D L; Sondak, V K; Hewitt, S M; Weeraratna, A T (2008): Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphor ylation. In: Cancer Research 68(24), 10205-10214 http://dx.doi.org/10.1158/0008-5472.CAN-08-2149


Dummer, R; Hauschild, A; Becker, J C; Grob, J J; Schadendorf, D; Tebbs, V; Skalsky, J; Kaelber, K C; Moosbauer, S; Clark, R; Meng, T C; Urosevic, M (2008): An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. In: Clinical Cancer Research 14(3), 856-864 http://dx.doi.org/10.1182/blood-2007-08-109074


Dummer, R; Rochlitz, C; Velu, T; Arcus, B; Limacher, J M; Bleuzen, P; Lacoste, G; Slos, P; Romero, P; Urosevic, M (2008): Intrallesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma. In: Molecular Therapy 16(5), 985-994 http://dx.doi.org/10.1038/mt.2008.32

Eggermont, A M M; Suciu, S; Santinami, M; Testori, A; Kruit, W H J; Marsden, J; Punt, C J A; Saës, F; Gore, M; Mackie, R; Ku sic, Z; Dummer, R; Hauschild, A; Musat, E; Spatz, A; Kelholz, U (2008): Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. In: Lancet 372(9633), 117-126 http://dx.doi.org/10.1016/S0140-6736(08)61033-8

Garbe, C; Radny, P; Linse, R; Dummer, R; Gutzmer, R; Ulrich, J; Stadler, R; Weichenthal, M; Eigentler, T K; Elwinger, U; Hauschild, A (2008): Adjuvant low-dose interferon [alpha]2a with or without dacarbazine compared with surger y alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. In: Annals of Oncology 19(6), 1195-1201 http://dx.doi.org/10.1093/annonc/mdn001
Garbe, C; Schadendorf, D; Stolz, W; Volkenandt, M; Reinhold, U; Kor tmann, R D; Kettelhack, C; Freich, B; Kehilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R; Haushild, A (2008): Short German guidelines: malignant melanoma. In: Journal der Deutschen Dermatologischen Gesellschaft 6(Suppl 1), S9-S14 http://dx.doi.org/10.1111/j.1610-0387.2008.06711.x


Golling, P; Cozzi, A; Dummer, R; French, L; Kempf, W (2008): Primary cutaneous B-cell lymphomas: clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. In: Leukemia and Lymphoma 49(6), 1094-1103 http://dx.doi.org/10.1080/10428190802064925

Guggenheim, M; Dummer, R; Jung, F J; Mihi-Probst, D; Steiner t, H; Rousson, V; French, L E; Giovannoli, P (2008): The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma - a retrospective analysis of 392 cases. In: British Journal of Cancer 98(12), 1922-1928 http://dx.doi.org/10.1038/sj.bjc.6604407


Hauschild, A; Dummer, R; Ugurel, S; Kaehler, K C; Egber ts, F; Fink, W; Both-Skalsky, I; Laetsch, B; Schadendorf, D (2008): Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. In: Cancer 113(6), 1404-1411 http://dx.doi.org/10.1002/cncr.23722

Hoek, K S; Eichhoff, O M; Schlegel, N C; Döbbeling, U; Kober t, N; Schaerer, L; Hemmi, S; Dummer, R (2008): In vivo switching of human melanoma cells between proliferative and invasive states. In: Cancer Research 68(3), 650-656 http://dx.doi.org/10.1158/0008-5472.CAN-07-2491

Hoek, K S; Schlegel, N C; Eichhoff, O M; Widmer, D S; Praetorius, C; Einarsson, S O; Valgeirsdottr, S; Borgsteinssott, K; Schepsky, A; Dummer, R; Steingrimsson, E (2008): Novel MITF targets identified using a two-step DNA microarray strategy. In: Pigment Cell & Melanoma Research 21(6), 665-676 http://dx.doi.org/10.1111/j.1755-148X.2008.00505.x


Johansen, P; Storni, T; Rettig, L; Qiu, Z; Der-Sarkissian, A; Smith, K A; Manolova, V; Lang, K S; Senti, G; Müllerhaub, B; Gerlach, T; Speck, R F; Bot, A M; Kündig, T M (2008): Antigen kinetics determines immune reactivity. In: Proceedings of the National Academy of Sciences of the United States of America 105(13), 5189-5194 http://dx.doi.org/10.1073/pnas.0706296105

Kazakov, D V; Kutzner, H; Spagnolo, D V; Kempf, W; Zelger, B; Mukensnabl, P; Michal, M (2008): Sebaceous differentiation in poroid neoplasms: report of 11 cases, including a case of metaplastic carcinoma associated with apocrine poroma (sarcomatoid apocrine porocarcinoma). In: American Journal of Dermatopathology 30(1), 21-26 http://dx.doi.org/10.1097/DAD.0b013e3181f2ae3
Sanchez-Politta, S; Favet, L; Kerl, K; Dietrich, P Y; Piquet, V (2008): Bortezomib-induced skin eruption. In: Dermatology 216(2), 156-158
http://dx.doi.org/10.1159/000111513

Schneider, M R; Antsiferova, M; Feldmeyer, L; Dahlhoff, M; Bugnon, P; Hasse, S; Paus, R; Wolf, E; Werner, S (2008): Betacellulin regulates hair follicle development and hair cycle induction and enhances angiogenesis in wounded skin. In: Journal of Investigative Dermatology 128(5), 1256-1265
http://dx.doi.org/10.1038/sj.jid.5701135

Schuler, P; Contassot, E; Irla, M; Hugues, S; Preynat-Seauve, O; Beermann, F; Donda, A; French, L E; Huard, B (2008): Direct presentation of a melanocyte-associated antigen in peripheral lymph nodes induces cytotoxic CD8+ T cells. In: Cancer Research 68(20), 8410-8418
http://dx.doi.org/10.1158/0008-5472.CAN-08-0809

Scibilia, J; Pastorello, E A; Zisa, G; Ottolenghi, A; Ballmer-Weber, B; Pravettoni, V; Scovena, E; Robino, A; Ortolani, C (2008): Maize food allergy: a double-blind placebo-controlled study. In: Clinical and Experimental Allergy 38(12), 1943-1949
http://dx.doi.org/10.1111/j.1365-2222.2008.03094.x

Scope, A; Dusza, S W; Halpern, A C; Rabinovitz, H; Braun, R P; Zalaudek, I; Argenziano, G; Marghoob, A A (2008): The "ugly duckling" sign: agreement between observers. In: Archives of Dermatology 144(1), 58-64
http://dx.doi.org/10.1001/archdermatol.2007.15

Senti, G; Prinz Vavricka, B M; Erdmann, J; Diaz, M I; Markus, R; McCormack, S J; Simard, J J; Wüthrich, B; Crameri, R; Graf, N; Johansen, P; Kündig, T M (2008): Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. In: Proceedings of the National Academy of Sciences of the United States of America 105(46), 17908-17912
http://dx.doi.org/10.1073/pnas.0803725105

Strobel, K; Dummer, R; Steiner, H C; Baumann Conzett, K; Schad, K; Pérez Lago, M; Soyka, J D; Veit-Halbach, P; Seifer, T B; Kalf, V (2008): Chemotherapy response assessment in stage IV melanoma patients-comparison of (18)F-FDG-PET/CT, CT, brain MRI, and tumormarker S-100B. In: European Journal of Nuclear Medicine and Molecular Imaging 35(10), 1786-1795
http://dx.doi.org/10.1007/s00259-008-0806-1

http://dx.doi.org/10.1111/j.1365-2230.2007.02644.x


Tun-Kyi, A; Qin, J Z; Oberholzer, P A; Navarini, A A; Hassel, J C; Dummer, R; Döbbeling, U (2008): Arsenic trioxide down-regulates antiapoptotic genes and induces cell death in mycosis fungoides tumors in a mouse model. In: Annals of Oncology 19(8), 1488-1494
http://dx.doi.org/10.1093/annonc/mdn056

Vieths, S; Reese, G; Ballmer-Weber, B K; Beyer, K; Burney, P; Fernandez-Rivas, M; Summers, C; van Ree, R; Mills, C (2008): The serum bank of EuroPrevall - the prevalence, cost and basis of food allergy across Europe. In: Food and Chemical Toxicology 46(10 Suppl 1), S12-S14
http://dx.doi.org/10.1016/j.fct.2008.07.020
Wang, S Q; Dusza, S W; Scope, A; Braun, R P; Kopf, A W; Marghoob, A A (2008): Differences in dermoscopic images from nonpolarized dermoscope and polarized dermoscope influence the diagnostic accuracy and confidence level: a pilot study. In: Dermatologic Surgery 34(10), 1389-1395
http://dx.doi.org/10.1111/j.1524-4725.2008.34293.x

Watanabe, H; Gehrke, S; Contassot, E; Roques, S; Tschopp, J; Friedmann, P S; French, L E; Gaide, O (2008): Danger signaling through the inflammasome acts as a master switch between tolerance and sensitization. In: Journal of Immunology 180(9), 5826-5832

Weibel, L; Har per, I (2008): Linear mor phoea follows Blaschko’s lines. In: British Journal of Dermatology 159(1), 175-181
http://dx.doi.org/10.1111/j.1365-2133.2008.08647.x


Zimmerli, S C; Kerl, K; Hadi-Rabia, S; Hohl, D; Hauser, C (2008): Human epidermal Langerhans cells express the tight junction protein claudin-1 and are present in human genetic claudin-1 deficiency (NISCH syndrome). In: Experimental Dermatology 17(1), 20-23
http://dx.doi.org/10.1111/j.1600-0625.2007.00624.x

Reviews, editorials & commentaries (reviewed)

http://dx.doi.org/10.1097/ACI.0b013e3282fbb157

http://dx.doi.org/10.1001/archdermatol.2007.21

Bregy, A; Trüeb, R M (2008): No association between serum ferritin levels >10 microg/l and hair loss activity in women. In: Dermatology 217(1), 1-6
http://dx.doi.org/10.1159/000118505

http://dx.doi.org/10.1038/jid.2008.49

Crevel, R W R; Ballmer-Weber, B K; Holzhauser, T; Hourihane, J O B; Knulst, A C; Mackie, A R; Timmermans, F; Taylor, S L (2008): Thresholds for food allergens and their value to different stakeholders. In: Allergy 63(5), 597-609
http://dx.doi.org/10.1111/j.1398-9995.2008.01636.x


http://dx.doi.org/10.1001/archderm.144.5.664


Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kor tmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008): Evidence and interdisciplinar y consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. In: Melanoma Research 18(1), 61-67

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kor tmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008): Evidence-based and interdisciplinar y consensus-based German guidelines: systemic medical treat ment of melanoma in the adjuvant and palliative setting. In: Melanoma Research 18(2), 152-160


http://dx.doi.org/10.1111/j.1755-148X.2008.00494.x

Hofbauer, G F L; Neuhaus Bühler, R P; French, L E; Brockes, M; Scheuer, E (2008): Patient-centered care in dermatology: an online system that provides accessible and appropriate information to guide patients’ decision making. In: Archives of Dermatology 144(9), 1225-1227
http://dx.doi.org/10.1001/archderm.144.9.1225

Khelifa, E; Tschanz, C; Masouyé, I; Kerl, K; Borradori, L (2008): A rare tumour of the nail apparatus: onychomatricoma. In: Journal of the European Academy of Dermatology and Venereology 22(9), 1127-1128
http://dx.doi.org/10.1111/j.1468-3083.2007.02531.x

http://dx.doi.org/10.1111/j.1365-2133.2008.08560.x

Pavlovic, M; Kamarachev, J; Adamic, M (2008): Primar y cutaneous epidermotropic marginal zone B-cell lymphoma: a role for antihistamines in maintaining lymphoma cell growth?. In: Journal of the European Academy of Dermatology and Venereology 22(8), 1012-1014
http://dx.doi.org/10.1111/j.1468-3083.2007.02522.x

http://dx.doi.org/10.1016/j.jaad.2008.06.018

Scherer, K; Ballmer-Weber, B K; Bircher, A J (2008): Highlights in nonhymenoptera anaphylaxis. In: Current Opinion in Allergy and Clinical Immunology 8(4), 348-353

Scope, A; Zalaudek, I; Ferrara, G; Argenziano, G; Braun, R P; Marghoob, A A (2008): Remodeling of the dermoepidermal junction in superficial spreading melanoma: insights gained from correlation of dermoscopy, reflectance confocal microscopy, and histopathologic analysis. In: Archives of Dermatology 144(12), 1644-1649
http://dx.doi.org/10.1001/archdermatol.2008.504

Stapel, S O; Asero, R; Ballmer-Weber, B K; Knol, E F; Strobel, S; Vieths, S; Kleine-Tebbe, J (2008): Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI task force repor t. In: Allergy 63(7), 793-796
http://dx.doi.org/10.1111/j.1398-9995.2008.01705.x

Steckelbroeck, S; Ballmer-Weber, B K; Vieths, S (2008): Potential, pitfalls, and prospects of food allergy diagnostics with recombinant allergens or synthetic sequential epito pes. In: Journal of Allergy and Clinical Immunology 121(6), 1323-1330
http://dx.doi.org/10.1016/j.jaci.2008.04.008


http://dx.doi.org/10.1055/s-2008-1077552

http://dx.doi.org/10.1007/s00105-008-1489-z

http://dx.doi.org/10.1158/0008-5472.CAN-07-2704

von Moos, R; Thuerlimann, B J K; Aapro, M; Rayson, D; Kamarachev, J; French, L E; Lademann, J; Hauschild, A (2008): Pegylated liposomal doxorubicin associated hand-foot syndrome: recommendations of an international panel of experts. In: European Journal of Cancer 44(6), 781-790
http://dx.doi.org/10.1016/j.ejca.2008.01.028


Reviews, editorials & commentaries (not reviewed)
http://dx.doi.org/10.1111/j.1610-0387.2008.06803.x


http://dx.doi.org/10.1111/j.1755-148X.2008.00494.x

Hofbauer, G F L; Neuhaus Bühler, R P; French, L E; Brockes, M; Scheuer, E (2008): Patient-centered care in dermatology: an online system that provides accessible and appropriate information to guide patients’ decision making. In: Archives of Dermatology 144(9), 1225-1227
http://dx.doi.org/10.1001/archderm.144.9.1225

Khelifa, E; Tschanz, C; Masouyé, I; Kerl, K; Borradori, L (2008): A rare tumour of the nail apparatus: onychomatricoma. In: Journal of the European Academy of Dermatology and Venereology 22(9), 1127-1128
http://dx.doi.org/10.1111/j.1468-3083.2007.02531.x

http://dx.doi.org/10.1111/j.1365-2133.2008.08560.x

Pavlovic, M; Kamarachev, J; Adamic, M (2008): Primar y cutaneous epidermotropic marginal zone B-cell lymphoma: a role for antihistamines in maintaining lymphoma cell growth?. In: Journal of the European Academy of Dermatology and Venereology 22(8), 1012-1014
http://dx.doi.org/10.1111/j.1468-3083.2007.02522.x

http://dx.doi.org/10.1016/j.jaad.2008.06.018

Scherer, K; Ballmer-Weber, B K; Bircher, A J (2008): Highlights in nonhymenoptera anaphylaxis. In: Current Opinion in Allergy and Clinical Immunology 8(4), 348-353

Scope, A; Zalaudek, I; Ferrara, G; Argenziano, G; Braun, R P; Marghoob, A A (2008): Remodeling of the dermoepidermal junction in superficial spreading melanoma: insights gained from correlation of dermoscopy, reflectance confocal microscopy, and histopathologic analysis. In: Archives of Dermatology 144(12), 1644-1649
http://dx.doi.org/10.1001/archdermatol.2008.504

Stapel, S O; Asero, R; Ballmer-Weber, B K; Knol, E F; Strobel, S; Vieths, S; Kleine-Tebbe, J (2008): Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI task force re-